Literature DB >> 433974

Regression of pituitary tumors, a possible effect of bromergocryptine.

S R George, G N Burrow, B Zinman, C Ezrin.   

Abstract

With the advent of the prolactin radioimmunoassay and more sensitive methods of roentgenologic examination, prolactin-secreting pituitary tumors are now being diagnosed with much greater frequency. Definitive treatment has been considered to involve transphenoidal hypophysectomy. The symptoms of hyperprolactinemia including amenorrhea, galactorrhea and infertility can usually be controlled without difficulty by bromergocryptine therapy, but little is known regarding continued tumor growth. Bromergocryptine and other ergot alkaloids have been shown to decrease the production of prolactin and to inhibit the rate of pituitary tumor growth in animal studies. In man, evidence for a similar effect is not as clear. The present study demonstrates tumor regression associated with bromergocryptine therapy in two patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 433974     DOI: 10.1016/0002-9343(79)91187-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

1.  Plasma prolactin in amenorrhoea, infertility, and other disorders: a retrospective study of 608 patients.

Authors:  P Skrabanek; D McDonald; E de Valera; O Lanigan; D Powell
Journal:  Ir J Med Sci       Date:  1980-06       Impact factor: 1.568

2.  The 'Alice in Wonderland' experience. Ergot alkaloid therapy for prolactin-secreting pituitary tumors.

Authors:  R C Williams; C Sherman; M T Buckman
Journal:  West J Med       Date:  1983-03

3.  The management of prolactin-secreting pituitary tumors.

Authors:  S R George; G N Burrow
Journal:  J Endocrinol Invest       Date:  1981 Oct-Dec       Impact factor: 4.256

4.  Bromocriptine treatment of macroprolactinomas: studies on the time course of tumor shrinkage and morphology.

Authors:  M Nissim; B Ambrosi; V Bernasconi; G Giannattasio; M A Giovanelli; M Bassetti; U Vaccari; P Moriondo; A Spada; P Travaglini; G Faglia
Journal:  J Endocrinol Invest       Date:  1982 Nov-Dec       Impact factor: 4.256

Review 5.  Gene therapy for pituitary tumors.

Authors:  Adriana Seilicovich; Daniel Pisera; Sandra A Sciascia; Marianela Candolfi; Mariana Puntel; Weidong Xiong; Gabriela Jaita; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

6.  Morphologic effects of bromocriptine on spontaneously occurring pituitary prolactin-cell hyperplasia in old Long-Evans rats.

Authors:  D J McComb; P Hellmann; M O Thorner; D Scott; W S Evans; K Kovacs
Journal:  Am J Pathol       Date:  1986-01       Impact factor: 4.307

7.  Reduction in size of prolactin-secreting tumours in men treated with pergolide.

Authors:  P Kendall-Taylor; K Hall; D G Johnston; R W Prescott
Journal:  Br Med J (Clin Res Ed)       Date:  1982-08-14

8.  Bromocriptine in management of large pituitary tumours.

Authors:  J A Wass; J Williams; M Charlesworth; D P Kingsley; A M Halliday; I Doniach; L H Rees; W I McDonald; G M Besser
Journal:  Br Med J (Clin Res Ed)       Date:  1982-06-26

9.  Effects of bromocriptine on pituitary tumour size.

Authors:  A M McGregor; M F Scanlon; R Hall; K Hall
Journal:  Br Med J       Date:  1979-09-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.